What exactly happens in the hearts of patients with heart failure with preserved ejection fraction (HFpEF)—and how can this ...

Cystatin C (CysC) is an independent risk factor for adverse outcomes in patients with HF across the ejection fraction (EF) spectrum.

People with mildly reduced ejection fraction, a distinct group with unique needs, account for nearly one-quarter of HF cases.

A review indicates obesity may amplify pathophysiology in HFrEF rather than acting as a primary cause, though weight loss data remain inconclusive.

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) commonly have improvements in their LVEF, but that doesn’t mean they can let their guard down, data from a large ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic, today announced U.S. Food and Drug ...